BACKGROUND: Adiponectin is an insulin-sensitizing, antiatherogenic and anti-inflammatory adipocytokine that circulates in three isoforms: a trimer [low-molecular weight (LMW)], a hexamer (trimer-dimer) of medium molecular weight (MMW) and a multimeric high molecular weight (HMW) isoform. Evidence is accumulating that HMW adiponectin is the active isoform of the adipocytokine. We investigated the impact of adipose tissue and insulin sensitivity on adiponectin isoform distribution. MATERIALS AND METHODS: One hundred and eighty-seven normolipidaemic, non-diabetic lean or obese subjects with or without insulin resistance participating in the Salzburg Atherosclerosis Prevention program in subjects at High Individual Risk (SAPHIR) were included in the study. Insulin sensitivity was determined by the short insulin tolerance test and the homeostasis model assessment (HOMA) index. Serum adiponectin isoform distribution was determined by an enzyme immunoassay. RESULTS: Total adiponectin as well as HMW/total adiponectin ratio was significantly increased in female subjects. Circulating total adiponectin levels were lowest in obese patients due to reduced concentrations of HMW adiponectin. As determined by stepwise regression analysis, besides age and high density lipoprotein (HDL) cholesterol, visceral fat area and waist-to-hip ratio predicted concentrations of HMW adiponectin, while insulin sensitivity had no influence on either total adiponectin or its isoforms. CONCLUSIONS: Our results underline that determination of adiponectin isoforms are more useful than measurement of total adiponectin in clinical settings. Our data suggest that adiponectin concentrations are strongly associated with visceral fat area but not with insulin sensitivity. Thus, we hypothesize that insulin resistance is a consequence rather than the cause of hypoadiponectinaemia in obese subjects.
BACKGROUND:Adiponectin is an insulin-sensitizing, antiatherogenic and anti-inflammatory adipocytokine that circulates in three isoforms: a trimer [low-molecular weight (LMW)], a hexamer (trimer-dimer) of medium molecular weight (MMW) and a multimeric high molecular weight (HMW) isoform. Evidence is accumulating that HMW adiponectin is the active isoform of the adipocytokine. We investigated the impact of adipose tissue and insulin sensitivity on adiponectin isoform distribution. MATERIALS AND METHODS: One hundred and eighty-seven normolipidaemic, non-diabetic lean or obese subjects with or without insulin resistance participating in the Salzburg Atherosclerosis Prevention program in subjects at High Individual Risk (SAPHIR) were included in the study. Insulin sensitivity was determined by the short insulin tolerance test and the homeostasis model assessment (HOMA) index. Serum adiponectin isoform distribution was determined by an enzyme immunoassay. RESULTS: Total adiponectin as well as HMW/total adiponectin ratio was significantly increased in female subjects. Circulating total adiponectin levels were lowest in obesepatients due to reduced concentrations of HMW adiponectin. As determined by stepwise regression analysis, besides age and high density lipoprotein (HDL) cholesterol, visceral fat area and waist-to-hip ratio predicted concentrations of HMW adiponectin, while insulin sensitivity had no influence on either total adiponectin or its isoforms. CONCLUSIONS: Our results underline that determination of adiponectin isoforms are more useful than measurement of total adiponectin in clinical settings. Our data suggest that adiponectin concentrations are strongly associated with visceral fat area but not with insulin sensitivity. Thus, we hypothesize that insulin resistance is a consequence rather than the cause of hypoadiponectinaemia in obese subjects.
Authors: Lucila Sackmann-Sala; Darlene E Berryman; Ellen R Lubbers; Clare B Vesel; Katie M Troike; Edward O List; Rachel D Munn; Yuji Ikeno; John J Kopchick Journal: Age (Dordr) Date: 2011-09-29
Authors: Lutz Hampe; Cheng Xu; Paul W R Harris; Jie Chen; Ming Liu; Martin Middleditch; Mazdak Radjainia; Yu Wang; Alok K Mitra Journal: Br J Pharmacol Date: 2017-11-02 Impact factor: 8.739
Authors: Lucila Sackmann-Sala; Darlene E Berryman; Rachel D Munn; Ellen R Lubbers; John J Kopchick Journal: Obesity (Silver Spring) Date: 2011-07-21 Impact factor: 5.002
Authors: Na Zhu; James S Pankow; Christie M Ballantyne; David Couper; Ron C Hoogeveen; Mark Pereira; Bruce B Duncan; Maria Inês Schmidt Journal: J Clin Endocrinol Metab Date: 2010-08-18 Impact factor: 5.958
Authors: Lucila Sackmann-Sala; Darlene E Berryman; Ellen R Lubbers; Han Zhang; Clare B Vesel; Katie M Troike; Elahu S Gosney; Edward O List; John J Kopchick Journal: J Gerontol A Biol Sci Med Sci Date: 2013-07-20 Impact factor: 6.053
Authors: Meilian Liu; Ruihua Xiang; Sarah Ann Wilk; Ning Zhang; Lauren B Sloane; Kian Azarnoush; Lijun Zhou; Hongzhi Chen; Guangda Xiang; Christi A Walter; Steven N Austad; Nicolas Musi; Ralph A DeFronzo; Reto Asmis; Philipp E Scherer; Lily Q Dong; Feng Liu Journal: Diabetes Date: 2012-07-17 Impact factor: 9.461
Authors: Hoi Kin Wong; Kwok Leung Ong; Raymond Y H Leung; Tommy T Cheung; Aimin Xu; Tai Hing Lam; Karen S L Lam; Bernard M Y Cheung Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240